These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery. Fischer HP Biotechnol Annu Rev; 2005; 11():1-68. PubMed ID: 16216773 [TBL] [Abstract][Full Text] [Related]
25. Globalization of quantitative pharmacology: first international symposium of quantitative pharmacology in drug development and regulation. Barrett JS; Shi J; Xie HT; Huang XH; Fossler MJ; Sun RY J Clin Pharmacol; 2008 Jul; 48(7):787-92. PubMed ID: 18490494 [TBL] [Abstract][Full Text] [Related]
26. Medical education in substance abuse: from student to practicing osteopathic physician. Wyatt SA; Vilensky W; Manlandro JJ; Dekker MA J Am Osteopath Assoc; 2005 Jun; 105(6 Suppl 3):S18-25. PubMed ID: 16118358 [TBL] [Abstract][Full Text] [Related]
27. Reflecting on 30 years of research. A look at how NIDA has advanced the research, prevention, and treatment of drug abuse and addiction. Condon TP Behav Healthc; 2006 May; 26(5):14, 16. PubMed ID: 16736912 [No Abstract] [Full Text] [Related]
28. Lipidomics: new tools and applications. Wenk MR Cell; 2010 Dec; 143(6):888-95. PubMed ID: 21145456 [TBL] [Abstract][Full Text] [Related]
29. Application of lipidomics and metabolomics to the study of adipose tissue. Mattila I; Seppänen-Laakso T; Suortti T; Oresic M Methods Mol Biol; 2008; 456():123-30. PubMed ID: 18516557 [TBL] [Abstract][Full Text] [Related]
30. Psychiatric research: psychoproteomics, degradomics and systems biology. Kobeissy FH; Sadasivan S; Liu J; Gold MS; Wang KK Expert Rev Proteomics; 2008 Apr; 5(2):293-314. PubMed ID: 18466058 [TBL] [Abstract][Full Text] [Related]
31. Lipidomics from an analytical perspective. Sandra K; Sandra P Curr Opin Chem Biol; 2013 Oct; 17(5):847-53. PubMed ID: 23830914 [TBL] [Abstract][Full Text] [Related]
32. Quantitative proteomics for drug toxicity. Gao Y; Holland RD; Yu LR Brief Funct Genomic Proteomic; 2009 Mar; 8(2):158-66. PubMed ID: 19351682 [TBL] [Abstract][Full Text] [Related]
33. Promises of biomarkers in drug development--a reality check. Marrer E; Dieterle F Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232 [TBL] [Abstract][Full Text] [Related]
35. Addiction research centres and the nurturing of creativity: The Swiss Institute for the Prevention of Alcohol and Drug Problems. Past, present and future. Kuntsche E; Maffli E; Kuntsche S; Delgrande Jordan M Addiction; 2009 May; 104(5):699-704. PubMed ID: 19413784 [TBL] [Abstract][Full Text] [Related]
36. Lipidomics: Prospects from a technological perspective. Triebl A; Hartler J; Trötzmüller M; C Köfeler H Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Aug; 1862(8):740-746. PubMed ID: 28341148 [TBL] [Abstract][Full Text] [Related]
37. High-throughput shotgun lipidomics by quadrupole time-of-flight mass spectrometry. Ståhlman M; Ejsing CS; Tarasov K; Perman J; Borén J; Ekroos K J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Sep; 877(26):2664-72. PubMed ID: 19286428 [TBL] [Abstract][Full Text] [Related]
38. Organizational and client determinants of cost in outpatient substance abuse treatment. Beaston-Blaakman A; Shepard D; Horgan C; Ritter G J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043 [TBL] [Abstract][Full Text] [Related]
39. The last decade of solvent research in animal models of abuse: mechanistic and behavioral studies. Bowen SE; Batis JC; Paez-Martinez N; Cruz SL Neurotoxicol Teratol; 2006; 28(6):636-47. PubMed ID: 17064879 [TBL] [Abstract][Full Text] [Related]